focus -WSS

focus

author：knowledge 2025-09-29 13:30:57 - browse：117

A view of different flags of the European Union Members. -- first opinion coverage from STAT — Ronald Wittek, Pool Photo via AP

Today, the criteria used to assess the clinical value of new pharmaceuticals and medical devices varies widely across Europe, making it more challenging for biopharma companies to efficiently launch products in multiple countries and contributing to the disparities in access across the continent.

But change is on the horizon: In less than 15 months, the European Union will establish and begin to implement a standardized, pan-EU framework, which all 27 of member states will be required to use to assess the clinical evidence of newly submitted products or devices. A key pillar of the EU’s Regulation on Health Technology Assessment (HTA), the Joint Clinical Assessment (JCA) aims to establish a single, transparent process to reduce redundant practices and bring life science innovation faster to patients in Europe — no matter where they live.

In a longstanding problem in Europe, access to — and the availability of — medication varies across the member states. For example, in Germany, 87% of products approved by the European Medicines Agency (EMA) have full availability (the product gained access on the public reimbursement list without any restrictions to the patient population). In Poland, that figure drops to 8%, according to a report published by the European Federation of Pharmaceutical Industries. Meanwhile, there is a tremendous difference in the gap between an oncology therapy receiving marketing authorization and a formal positive reimbursement decision, ranging from an average of 86 days in Denmark to 981 days in Latvia.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： The Readout: Lenmeldy, GLP

knowledge

explore

WSS

Abortion pill case raises question: who can sue the FDA?

There's no autism epidemic. It's an autism diagnosis epidemic

Readout LOUD podcast: mifepristone case, GLP

'The View' co

Grand jury probing Trump's efforts to overturn 2020 election did not meet Friday: Sources

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

Wikipedia

focus

leisure time

New air purifier tech could be key to improving indoor air quality

Covid vaccine financial winners and losers, from Pfizer to Novavax

Medical records are filled with copy

Will generative AI in health care meet the fate of IBM's Dr. Watson?

Bright Health sells Medicare Advantage business to Molina

Reframing the conversation around gain

FDA approval of Sarepta Duchenne genetic therapy gives me hope

The Readout: Lenmeldy, GLP

Bright Health sells Medicare Advantage business to Molina

There's no autism epidemic. It's an autism diagnosis epidemic

leisure time

What is artificial intelligence? Experts weigh in

Why Marc Tessier

Scientists boost immune system in aging mice by making it youthful

New chief aims to remake Sanofi Genzyme

New chart reveals military’s vast involvement in Operation Warp Speed

Mega Millions jackpot grows to $720 million ahead of Friday's drawing

hotspot

knowledge

explore

explore